199 related articles for article (PubMed ID: 29754968)
1. Recurrent pseudoprogression in isocitrate dehydrogenase 1 mutant glioblastoma.
Kebir S; Rauschenbach L; Gielen GH; Schäfer N; Tzaridis T; Scheffler B; Giordano FA; Lazaridis L; Herrlinger U; Glas M
J Clin Neurosci; 2018 Jul; 53():255-258. PubMed ID: 29754968
[TBL] [Abstract][Full Text] [Related]
2. Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET.
Kebir S; Fimmers R; Galldiks N; Schäfer N; Mack F; Schaub C; Stuplich M; Niessen M; Tzaridis T; Simon M; Stoffels G; Langen KJ; Scheffler B; Glas M; Herrlinger U
Clin Cancer Res; 2016 May; 22(9):2190-6. PubMed ID: 26673798
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET.
Galldiks N; Dunkl V; Stoffels G; Hutterer M; Rapp M; Sabel M; Reifenberger G; Kebir S; Dorn F; Blau T; Herrlinger U; Hau P; Ruge MI; Kocher M; Goldbrunner R; Fink GR; Drzezga A; Schmidt M; Langen KJ
Eur J Nucl Med Mol Imaging; 2015 Apr; 42(5):685-95. PubMed ID: 25411133
[TBL] [Abstract][Full Text] [Related]
4. Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET).
Bashir A; Mathilde Jacobsen S; Mølby Henriksen O; Broholm H; Urup T; Grunnet K; Andrée Larsen V; Møller S; Skjøth-Rasmussen J; Skovgaard Poulsen H; Law I
Neuro Oncol; 2019 Dec; 21(12):1595-1606. PubMed ID: 31618420
[TBL] [Abstract][Full Text] [Related]
5. Refinement of response assessment in neuro-oncology (RANO) using non-enhancing lesion type and contrast enhancement evolution pattern in IDH wild-type glioblastomas.
Moon HH; Kim HS; Park JE; Kim YH; Kim JH
BMC Cancer; 2021 Jun; 21(1):654. PubMed ID: 34074252
[TBL] [Abstract][Full Text] [Related]
6. Clinical Utility of Different Approaches for Detection of Late Pseudoprogression in Glioblastoma With O-(2-[18F]Fluoroethyl)-L-Tyrosine PET.
Kertels O; Mihovilovic MI; Linsenmann T; Kessler AF; Tran-Gia J; Kircher M; Brumberg J; Monoranu CM; Samnick S; Ernestus RI; Löhr M; Meyer PT; Lapa C
Clin Nucl Med; 2019 Sep; 44(9):695-701. PubMed ID: 31274552
[TBL] [Abstract][Full Text] [Related]
7. Unsupervised consensus cluster analysis of [18F]-fluoroethyl-L-tyrosine positron emission tomography identified textural features for the diagnosis of pseudoprogression in high-grade glioma.
Kebir S; Khurshid Z; Gaertner FC; Essler M; Hattingen E; Fimmers R; Scheffler B; Herrlinger U; Bundschuh RA; Glas M
Oncotarget; 2017 Jan; 8(5):8294-8304. PubMed ID: 28030820
[TBL] [Abstract][Full Text] [Related]
8. Correlation of Dynamic O-(2-[
Lohmann P; Piroth MD; Sellhaus B; Weis J; Geisler S; Oros-Peusquens AM; Mohlberg H; Amunts K; Shah NJ; Galldiks N; Langen KJ
World Neurosurg; 2018 Nov; 119():e653-e660. PubMed ID: 30077752
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma.
Bette S; Gempt J; Delbridge C; Kirschke JS; Schlegel J; Foerster S; Huber T; Pyka T; Zimmer C; Meyer B; Ringel F
World Neurosurg; 2016 May; 89():230-9. PubMed ID: 26855307
[TBL] [Abstract][Full Text] [Related]
10. MRI and
Wirsching HG; Roelcke U; Weller J; Hundsberger T; Hottinger AF; von Moos R; Caparrotti F; Conen K; Remonda L; Roth P; Ochsenbein A; Tabatabai G; Weller M
Clin Cancer Res; 2021 Jan; 27(1):179-188. PubMed ID: 32967939
[TBL] [Abstract][Full Text] [Related]
11. PET/MR in recurrent glioblastoma patients treated with regorafenib: [
Lombardi G; Spimpolo A; Berti S; Campi C; Anglani MG; Simeone R; Evangelista L; Causin F; Zorzi G; Gorgoni G; Caccese M; Padovan M; Zagonel V; Cecchin D
Br J Radiol; 2022 Jan; 95(1129):20211018. PubMed ID: 34762492
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis of Pseudoprogression Following Lomustine-Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET.
Werner JM; Weller J; Ceccon G; Schaub C; Tscherpel C; Lohmann P; Bauer EK; Schäfer N; Stoffels G; Baues C; Celik E; Marnitz S; Kabbasch C; Gielen GH; Fink GR; Langen KJ; Herrlinger U; Galldiks N
Clin Cancer Res; 2021 Jul; 27(13):3704-3713. PubMed ID: 33947699
[TBL] [Abstract][Full Text] [Related]
13. Can Early Postoperative O-(2-
Buchmann N; Gempt J; Ryang YM; Pyka T; Kirschke JS; Meyer B; Ringel F
World Neurosurg; 2019 Jan; 121():e467-e474. PubMed ID: 30267942
[TBL] [Abstract][Full Text] [Related]
14. O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma.
Pöpperl G; Goldbrunner R; Gildehaus FJ; Kreth FW; Tanner P; Holtmannspötter M; Tonn JC; Tatsch K
Eur J Nucl Med Mol Imaging; 2005 Sep; 32(9):1018-25. PubMed ID: 15877226
[TBL] [Abstract][Full Text] [Related]
15. [
Koh ES; Gan HK; Senko C; Francis RJ; Ebert M; Lee ST; Lau E; Khasraw M; Nowak AK; Bailey DL; Moffat BA; Fitt G; Hicks RJ; Coffey R; Verhaak R; Walsh KM; Barnes EH; De Abreu Lourenco R; Rosenthal M; Adda L; Foroudi F; Lasocki A; Moore A; Thomas PA; Roach P; Back M; Leonard R; Scott AM
BMJ Open; 2023 Aug; 13(8):e071327. PubMed ID: 37541751
[TBL] [Abstract][Full Text] [Related]
16. Vascular architecture mapping for early detection of glioblastoma recurrence.
Stadlbauer A; Eyüpoglu I; Buchfelder M; Dörfler A; Zimmermann M; Heinz G; Oberndorfer S
Neurosurg Focus; 2019 Dec; 47(6):E14. PubMed ID: 31786560
[TBL] [Abstract][Full Text] [Related]
17. O-(2-(
Mihovilovic MI; Kertels O; Hänscheid H; Löhr M; Monoranu CM; Kleinlein I; Samnick S; Kessler AF; Linsenmann T; Ernestus RI; Buck AK; Lapa C
J Neurol Neurosurg Psychiatry; 2019 Feb; 90(2):238-239. PubMed ID: 29705720
[No Abstract] [Full Text] [Related]
18. Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI.
Galldiks N; Langen KJ; Holy R; Pinkawa M; Stoffels G; Nolte KW; Kaiser HJ; Filss CP; Fink GR; Coenen HH; Eble MJ; Piroth MD
J Nucl Med; 2012 Jul; 53(7):1048-57. PubMed ID: 22645298
[TBL] [Abstract][Full Text] [Related]
19. Pseudoprogression on 68Ga-Prostate-Specific Membrane Antigen-11 PET/CT in a Treated Glioblastoma.
Gupta M; Choudhury PS; Gairola M; Premsagar IC; Rao SA
Clin Nucl Med; 2020 Aug; 45(8):621-622. PubMed ID: 32520501
[TBL] [Abstract][Full Text] [Related]
20. (18)F-Fluoroethyl-l-Thyrosine Positron Emission Tomography to Delineate Tumor Residuals After Glioblastoma Resection: A Comparison with Standard Postoperative Magnetic Resonance Imaging.
Buchmann N; Kläsner B; Gempt J; Bauer JS; Pyka T; Delbridge C; Meyer B; Krause BJ; Ringel F
World Neurosurg; 2016 May; 89():420-6. PubMed ID: 26893043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
